Related Experiment Videos
Combination therapy for nocturnal enuresis with desmopressin and an alarm device
1School of Medicine, Division of Paediatrics and Child Health, St. James's Hospital, Leeds, UK.
Insights
Combining alarm therapy with desmopressin nasal spray significantly improves nighttime dryness in children with nocturnal enuresis. This combination therapy is especially effective for severe wetting and behavioral issues.
Area of Science:
- Pediatric Nephrology
- Sleep Medicine
- Urology
Background:
- Nocturnal enuresis is a common condition affecting children's quality of life.
- Alarm monotherapy is a standard treatment, but success rates can vary.
- Desmopressin is a synthetic analog of vasopressin used to reduce urine production.
Purpose of the Study:
- To compare the efficacy of alarm monotherapy versus combination therapy (alarm + desmopressin) for childhood nocturnal enuresis.
- To evaluate treatment outcomes in children with varying degrees of enuresis severity and co-occurring problems.
Main Methods:
- A comparative study involving 71 children with nocturnal enuresis.
- Group 1: Alarm monotherapy (35 children).
- Group 2: Alarm therapy combined with desmopressin nasal spray (36 children).
Main Results:
- Combination therapy resulted in more dry nights per week (mean 6.1) compared to alarm monotherapy (mean 4.8).
- Higher initial success rates (4 weeks of dryness) were observed with combination therapy (75%) versus alarm monotherapy (46%).
- Improvements were more pronounced in children with severe wetting, family, or behavioral problems.
Conclusions:
- Alarm therapy supplemented with desmopressin is more effective than alarm monotherapy for treating childhood nocturnal enuresis.
- This combined approach is particularly beneficial for children with severe enuresis or associated behavioral issues.
- Consideration of desmopressin augmentation for specific pediatric populations can enhance treatment outcomes.
Abstract:
The efficacy of alarm monotherapy (35 children) was compared with the efficacy of alarm treatment in combination with 40 micrograms desmopressin (Minirin, DDAVP) nasal spray (36 children). At the end of the treatment period, children receiving combination therapy had more dry nights per week (mean: 6.1) than children using an alarm alone (mean: 4.8). In addition, more children achieved an initial success (4 weeks of dryness) following combination treatment (27 children [75%]) compared with alarm monotherapy (16 children [46%], P < 0.005). This improvement with alarm plus desmopressin was particularly pronounced in children with severe wetting (> or = 6 nights per week), family problems or behavioural problems. It may, therefore, be appropriate to manage children in these categories with an enuresis alarm supplemented with desmopressin to improve treatment outcome.